Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Dexilant (dexlansoprazole) delayed-release capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 

 

May 2012

Summary View

5 WARNINGS AND PRECAUTIONS

5.4 Concomitant Use of DEXILANT with Methotrexate
  • Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients [see Drug Interactions (7.5)].

7 DRUG INTERACTIONS

7.5 Methotrexate
  • Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate .....

 

 

October 2011 

Summary View

 

DRUG INTERACTIONS

Clopidogrel
  • section added....

 

also see:

 

CLINICAL PHARMACOLOGY

Pharmacokinetics
  • Clopidogrel.....

 

-
-